VEGF gene delivery for treatment of ischemic cardiovascular disease

Mark L. Koransky, Robert C. Robbins, Helen M. Blau

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations


There are increasing numbers of patients with ischemic myocardial disease not amenable to traditional methods of revascularization. These patients may benefit from new research into the use of naturally occurring angiogenic compounds, such as vascular endothelial growth factor (VEGF) for re-establishing blood flow into regions of hibernating myocardium. Animal studies and human clinical trials evaluating VEGF demonstrate increases in myocardial perfusion after treatment, with some patients reporting improvement in anginal symptoms. Further research into the ideal form of VEGF therapy (protein, plasmid, or adenoviral) and delivery method (intracoronary, intramyocardial, or epicardial) seems justified.

Original languageEnglish (US)
Pages (from-to)108-114
Number of pages7
JournalTrends in Cardiovascular Medicine
Issue number3
StatePublished - 2002
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'VEGF gene delivery for treatment of ischemic cardiovascular disease'. Together they form a unique fingerprint.

Cite this